Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cash from Financing Activities of $21000.0 for Q1 2026, down 98.44% year-over-year from $1.3 million in Q1 2025, and down 93.4% quarter-over-quarter from $318000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cash from Financing Activities for 17 consecutive years, with $21000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 98.44% year-over-year to $21000.0; the TTM figure through Mar 2026 stood at $23.1 million (up 726.94% YoY), while the FY2025 annual figure was $24.4 million, up 1059.75% from the prior year.
- Cash from Financing Activities fell to $21000.0 in Q1 2026 per GYRE's latest filing, from $318000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $22.4 million in Q2 2025 and bottomed at -$45.0 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged -$1.1 million across 5 years, with a median of $318000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 48612.5% — and 2025, when it jumped 14227.56%.
- Gyre Therapeutics' Cash from Financing Activities stood at -$45.0 million in 2022, then soared by 133.85% to $15.2 million in 2023, then slumped by 93.67% to $964000.0 in 2024, then slumped by 67.01% to $318000.0 in 2025, then sank by 93.4% to $21000.0 in 2026.
- Business Quant data shows GYRE's Cash from Financing Activities at $21000.0 in Q1 2026, $318000.0 in Q4 2025, and $365000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -8,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 20.25 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 964,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Dec 31, 2023 | 15.24 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -3.50 Mn |
| Mar 31, 2023 | -7.76 Mn |
| Sep 30, 2022 | -45.03 Mn |
| Mar 31, 2022 | 16,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | 49.46 Mn |
| Sep 30, 2020 | -75,000.00 |